TCR-Based Antigen-Specific Therapy for Type 1 Diabetes Mellitus: From Editing Autoreactive Clones to Tolerance...

Area of Science:

• Immunology
• Endocrinology
• Cellular Biology

Background:

• Type 1 diabetes mellitus (T1DM) is an autoimmune disease destroying insulin-producing pancreatic beta cells.
• Current T1DM treatments often fail to halt the autoimmune process or restore beta-cell function.

Purpose of the Study:

• To review T cell receptor (TCR)-based treatment strategies for T1DM.
• To explore selective elimination of pathogenic T cells and immune tolerance induction via TCR-modified regulatory T cells (TCR-Tregs).

Main Methods:

• Identification of key islet autoantigens and pathogenic TCRs.
• Review of methodologies for TCR detection and TCR-Treg generation.
• Examination of TCR-Treg mechanisms and impact on immune cells.

Main Results:

• TCR-based therapies focus on eliminating autoreactive T cells and inducing tolerance.
• TCR-Tregs show potential in modulating immune responses in T1DM.
• CD8+ T regulatory cells are also considered for therapeutic applications.

Conclusions:

• TCR-based therapy offers a specific and potentially revolutionary approach to T1DM treatment.
• Future directions include optimizing TCR affinity, Treg stability, and combination therapies.
• This approach aims to restore immune tolerance with reduced systemic immunosuppression.